SLC25A25-AS1 was significantly downregulated in CRC tumour tissues, but its overexpression resulted in cell proliferation inhibition and increased DOX sensitivity, while its downregulation enhanced chemoresistance and promoted EMT by activating the ERK/MAPK signalling pathway through ERK and p38. This evidence concerns the gene SLC25A25 and colorectal carcinoma.